Elevation of YKL-40 in the CSF of Anti-NMDAR Encephalitis Patients Is Associated With Poor Prognosis

Jinyu Chen¹, Yuewen Ding¹, Dong Zheng², Zhanhang Wang³, Suyue Pan¹, Teng Ji⁴, Hai-Ying Shen⁵* and Honghao Wang¹*

¹ Department of Neurology, Nanfang Hospital, Southern Medical University, Guangzhou, China, ² Department of Neurology, The Affiliated Brain Hospital of Guangzhou Medical University, Guangzhou, China, ³ Department of Neurology, 39 Brain Hospital, Guangzhou, China, ⁴ Department of Neurology, Randall Children’s Hospital, Legacy Health, Portland, OR, United States, ⁵ RS Dow Neurobiology Laboratories, Legacy Research Institute, Legacy Health, Portland, OR, United States

Objective: Anti-N-methyl-D-aspartate receptor (NMDAR) encephalitis predominantly affects children and young women; the disease can have a multistage presentation and exhibit a wide variety of neuropsychiatric features. This study aimed to investigate the profile of YKL-40 (Chitinase 3-like 1) in anti-NMDAR encephalitis patients and evaluate its association with modified Rankin Scale (mRS) scores and expression of inflammatory cytokines.

Methods: A total of 66 patients were enrolled in this study, 33 with anti-NMDAR encephalitis, 13 with viral meningitis and 20 with non-inflammatory neurological disease. Patients were evaluated to determine mRS scores at disease onset and at the 3 month follow-up; cerebrospinal fluid (CSF) samples were collected in the meantime. CSF levels of YKL-40 and cytokines (TNF-α, IL-6, IL-10) were measured by enzyme-linked immunosorbent assay.

Results: CSF levels of YKL-40 and inflammatory cytokines (TNF-α, IL-6, IL-10) were all more highly elevated in patients with anti-NMDAR encephalitis at the acute stage of disease compared with the controls. Levels of CSF YKL-40 were correlated with levels of IL-6 both at disease onset and at the 3 month follow-up. Changes in YKL-40 levels were significantly correlated with improved mRS scores in patients with anti-NMDAR encephalitis.

Conclusion: Our study suggests that CSF levels of YKL-40 in patients with anti-NMDAR encephalitis were increased and correlated with clinical mRS scores. This may be reflective of the underlying neuroinflammatory process. YKL-40 demonstrates potential as a possible biomarker for the prognosis of anti-NMDAR encephalitis.

Keywords: anti-NMDAR encephalitis, cerebrospinal fluid, YKL-40, modified rankin scale, cytokines
INTRODUCTION

Anti-N-methyl-D-aspartate receptor (NMDAR) encephalitis is a newly recognized acute form of encephalitis caused by anti-neuronal autoantibody; anti-NMDAR encephalitis is potentially lethal and mainly affects children and young women (1, 2). Anti-NMDAR encephalitis can develop with multistage presentation and a wide spectrum of neuropsychiatric features. The early-phase involves nonspecific prodromes such as fatigue, fever and headache. In late-phase, impaired consciousness, cognitive deficits, seizures, profound psychiatric symptoms, dysautonomia, and central hypoventilation often emerge, necessitating intensive care treatment (3–5). One of the challenges for management of anti-NMDAR encephalitis is the lack of available biomarkers for monitoring and predicting prognosis. The hallmarks of neuroinflammation in anti-NMDAR encephalitis should be thoroughly investigated to improve treatment and patient outcomes.

Anti-NMDAR encephalitis is caused by autoantibodies which primarily target the NR1 subunit of the NMDAR. Transformation of B and T lymphocytes is thought to be involved in the inflammatory injury that occurs with anti-NMDAR encephalitis (6). Gliosis, microglia proliferation and IgG deposition are suggested to be the most prominent histopathological features of the disease (7). YKL-40 (chitinase 3-like 1 or Hcgp39) is a secreted glycoprotein belonging to the glycosyl hydrolase 18 family. In the central nervous system (CNS), YKL-40 is mostly expressed by microglia, especially when responding to acute and chronic inflammation (8, 9). An increase of YKL-40 in the brain and/or cerebrospinal fluid (CSF) is associated with a variety of immune and inflammatory diseases, particularly neurological and neurodegenerative diseases with an inflammatory component, such as multiple sclerosis (MS), Alzheimer’s disease (AD), and stroke (10–12). However, little is known about what inflammatory mediators regulate YKL-40 or the underlying molecular mechanisms behind this regulation. In the present study, we aimed to investigate the YKL-40 profile in patients with anti-NMDAR encephalitis and to evaluate possible associations between YKL-40 and modified Rankin Scale (mRS) scores, as well as the expression of inflammatory cytokines.

MATERIALS AND METHOD

Patients and Controls

This study enrolled 33 patients with anti-NMDAR encephalitis, 13 patients with viral meningitis (VM) and 20 controls. The diagnosis of anti-NMDAR encephalitis was confirmed using criteria which included the presence of clinical manifestations and detection of anti-NMDAR antibodies in the CSF using a cell-based assay (2, 13). Patients with non-inflammatory neurological disease were used as controls, including 15 cases of mild white matter degeneration and 6 cases of movement disorders.

Abbreviations: AD, Alzheimer’s disease; CSF, Cerebrospinal fluid; CNS, Central nervous system; ELISA, Enzyme-linked immunosorbent assay; MS, Multiple sclerosis; mRS, modified Rankin Scale; NMDAR, N-methyl-D-aspartate receptor; NF-kB, Nuclear factor-kappa B; STAT3, Signal transducer and activator of transcription 3.

RESULTS

Increased CSF Levels of YKL-40 and Cytokines in Patients With Anti-NMDAR Encephalitis

To investigate the role of YKL-40 in anti-NMDAR encephalitis, we measured the CSF level of YKL-40 in patients with anti-NMDAR encephalitis (n = 33), VM (n = 13), and controls (n = 20) using an ELISA assay. As shown in Figure 1A, the levels of YKL-40 in the CSF of anti-NMDAR encephalitis patients at the onset of disease (median 128.3 pg/mL; interquartile range 97–171.4 pg/mL) were significantly higher than those of VM...
### Table 1 | The demographic data of patients with anti-NMDAR encephalitis (n = 33), viral meningitis (n = 13) and controls (n = 20).

| Characteristic                        | Anti-NMDAR encephalitis | Viral meningitis | Controls |
|---------------------------------------|--------------------------|------------------|----------|
| Gender (female/male)                  | 19/14                    | 5/8              | 13/8     |
| Age (years, mean ± SD)               | 34.8 ± 17.5              | 35.7 ± 15.7      | 34.81 ± 13.32 |
| Symptom onset (n, %)                  |                          |                  |          |
| Prodromal symptoms                   | 16 (48.5)                | 0                | –        |
| Psychiatric symptoms                 | 32 (97.0)                | 2                | –        |
| Memory deficits                      | 6 (18.2)                 | 3                | –        |
| Speech disturbances                  | 2 (6.0)                  | 0                | –        |
| Seizures                              | 22 (66.7)                | 1                | –        |
| Movement disorders                   | 7 (21.2)                 | 0                | –        |
| Loss of consciousness                | 21 (63.6)                | 0                | –        |
| Central hypoventilation              | 7 (21.2)                 | 0                | –        |
| Ovarian teratoma                     | 2 (6.1)                  | 0                | –        |
| mRS                                   | 4.2 ± 0.9                | –                | –        |
| 3 month mRS                           | 2.7 ± 1.2                | –                | –        |
| CSF anti-NMDAR antibody               | 33                       | 0                | 0        |
| Treatment (n, %)                      |                          |                  |          |
| First line treatment                  | 22 (66.7)                | –                | –        |
| Second-line treatment                 | 11 (33.3)                | –                | –        |
| Onset                                 |                          |                  |          |
| YKL-40 (pg/ml)*                       | 128.3 (97.0–171.4)       | 94.7 (77.1–113.6) | 82.4 (67.4–93.4) |
| TNF-α (pg/ml)                         | 6.0 (4.3–11.3)           | 5.27 (3.4–11.3)  | 1.1 (0.2–2.2) |
| IL-6 (pg/ml)                          | 7.3 (3.9–13.4)           | 4.6 (3.4–6.7)    | 3.1 (2.7–4.1) |
| IL-10 (pg/ml)                         | 4.9 (3.6–5.8)            | 3.21 (2.0–5.7)   | 0.9 (0–1.1)  |
| 3 month follow-up                     |                          |                  |          |
| YKL-40 (pg/ml)                        | 121.1 (106.4–173.0)      | –                | –        |
| TNF-α (pg/ml)                         | 3.5 (2.31–8.3)           | –                | –        |
| IL-6 (pg/ml)                          | 7.3 (5.7–8.2)            | –                | –        |
| IL-10 (pg/ml)                         | 2.7 (1.3–4.8)            | –                | –        |

*Data were presented as the median (interquartile range).*

patients (94.7 pg/mL; 77.1–113.6 pg/mL) and controls (82.4 pg/mL; 67.35–93.35 pg/mL) (p = 0.017, p < 0.001, respectively).

CSF levels of the pro-inflammatory cytokines TNF-α and IL-6 were significantly higher in anti-NMDAR encephalitis patients than in controls (p < 0.001 for both cytokines). The anti-inflammatory cytokine IL-10 was also higher in the anti-NMDAR patients than in controls (p < 0.001) (Table 1, Figure 1B). In the acute stage, a positive association was observed between YKL-40 and IL-6 levels (r = 0.549, p < 0.001) (Figure 1D). ROC curves for YKL-40 were calculated using data from all 66 patients. The area under the ROC curve (AUC) was 0.9091 and the optimal cut-off value was 118.8 pg/mL (Figure 1C), indicate that YKL-40 has a potential diagnostic value of anti-NMDAR encephalitis.

**Altered CSF Levels of YKL-40 and Cytokines in the Follow-Up for Anti-NMDAR Encephalitis Patients**

CSF levels of YKL-40 in patients decreased significantly from 128.3 pg/mL (97.0–171.4 pg/mL) (onset) to 121.1 pg/mL (106.4–173 pg/mL) (3 month follow-up) (p = 0.015), although the latter was still higher than controls (p < 0.001). CSF levels of IL-10, TNF-α and IL-6 at the 3 month follow-up were significantly lower than those at the onset of disease. (p < 0.01 for all cytokines). In addition, the decrease in CSF YKL-40 levels was positively associated with the change in IL-6 levels and improvement of mRS scores (Figures 1E,F).

**DISCUSSION**

Neuroinflammation is a common feature of anti-NMDAR encephalitis pathology; increasing evidence suggests that inflammatory cytokines and immune cells are important effectors and regulators for the inflammation and autoimmunity associated with this disease (7, 15–18). Autopsy studies using patient brain tissues showed that B cells interact with T cells and macrophages, inducing neuroinflammation (15, 19). YKL-40 levels have been reported in patients with several neuroinflammatory and neurodegenerative diseases (20). It can be expressed in macrophages/microglial cells and has been proposed as a potential marker for ongoing inflammation in a variety of human diseases (21–24). In the present study, we showed that CSF YKL-40 levels were significantly increased in patients with anti-NMDAR encephalitis and the change in YKL-40 levels at follow-up correlated positively with the improvement of mRS. Our results were similar to those reported
for YKL-40 from MS and AD studies (25, 26). Elevated YKL-40 levels during acute attacks of anti-NMDAR encephalitis were significantly reduced after effective treatment, which was correlated with the severity of disease (mRS). Reduced levels of YKL-40 in CSF may be attributed to (i) reduced production of YKL-40 from relieved inflammation and tissue damage in the CNS after treatment; and/or (ii) reduced pro-inflammatory effect of YKL-40, which is similar to the possible associated mechanisms of YKL-40 after immunotherapy in MS (27). In our study, the 15 patients that were seen at follow-up were all treated with immunotherapy, which could have affected YKL-40 levels.

We also demonstrated that CSF levels of IL-6, a pro-inflammatory cytokine, significantly increased in anti-NMDAR encephalitis patients. IL-6 is a cytokine that is able to cause a robust, cytokine-driven expression of YKL-40 in astrocytes, which requires use of both the STAT3 and NF-κB binding elements on the YKL-40 promoter (28). Studies have shown that increased IL-6 in CSF and brain tissue could facilitate production of intrathecal anti-NMDAR autoantibody in encephalitis (29, 30). The role of IL-6 in the regulation of YKL-40 is also supported by in vitro experiments and observations in patient studies (31). In this study, we found that the changes in IL-6 correlated with changes in YKL-40, suggesting that IL-6 may contribute to YKL-40 expression and the autoantibody-induced neurological deficits observed in anti-NMDAR encephalitis.

Our study has several limitations. First, the sample size was relatively small, caution should be exercised when interpreting these results. In addition, YKL-40 is not disease specific and may be involved in other medical conditions including vascular risk factors and acute infectious diseases, all of which may affect the diagnose value of YKL-40. Finally, this was just a preliminary study, the mechanism of the increases YKL-40 in anti-NMDAR encephalitis patients remain unclear, which should be elucidated with further studies.

**CONCLUSIONS**

We report, for the first time, the role of YKL-40 in anti-NMDAR encephalitis. Changes in CSF YKL-40 levels positively correlated with improvement of mRS, suggesting that YKL-40 may be implicated in the pathogenesis of anti-NMDAR encephalitis. To fully understand the role YKL-40 is playing in anti-NMDAR encephalitis, additional mechanistic and experimental studies should be conducted in the future.

**ETHICS STATEMENT**

The study was conducted with the approval of the Ethics Committee of Nanfang Hospital, Southern Medical University.

**AVAILABILITY OF DATA AND MATERIAL**

We declared that materials described in the manuscript, including all relevant raw data, will be freely available to any scientist wishing to use them for non-commercial purposes, without breaching participant confidentiality.
AUTHOR CONTRIBUTIONS

HW, H-YS, and SP co-conceived this study and designed the experiments. JC, DZ, and ZW collected the CSF samples and clinical data. JC, YD, and TJ performed the experiments and analyzed the data. JC, YD, and HW wrote the manuscript and prepared the table/figures. All authors read and approved the final manuscript and agreed to submit it for publication.

REFERENCES

1. Titulaer MJ, McCracken L, Gabilondo I, Armanagué T, Glaser C, Iizuka T, et al. Treatment and prognostic factors for long-term outcome in patients with anti-NMDA receptor encephalitis: an observational cohort study. *Lancet Neurol.* (2013) 12:157–65. doi: 10.1016/S1474-4422(12)70310-1
2. Dalmau J, Tüzün E, Wu HY, Masjuan J, Rossi JF, Voloschin A, et al. Paraneoplastic anti-N-methyl-D-aspartate receptor encephalitis associated with ovarian teratoma. *Ann Neurol.* (2007) 61:25–36. doi: 10.1002/ana.21050
3. de Bruijn MAAM, Aarsen FK, van Oosterhout MP, van der Knoop MM, Catsman-Berrevoets CE, Schreurs MWJ, et al. Long-term neuropsychological outcome following pediatric anti-NMDAR encephalitis. *Neurology* (2018) 90:e1997–e2005. doi: 10.1212/WNL.0000000000005605
4. Zheng F, Ye X, Shi X, Poonit ND, Lin Z. Management of refractory orofacial dyskinesia caused by anti-N-methyl-D-aspartate receptor encephalitis using botulinum toxin. *Front Neurol.* (2018) 9:81. doi: 10.3389/fneur.2018.00081
5. Vincent A, Bien CG. Anti-NMDA receptor encephalitis: a cause of psychiatric, seizure, and movement disorders in young adults. *Lancet Neurol.* (2008) 7:1074–5. doi: 10.1016/S1474-4422(08)70225-4
6. Dalmau J, Gleichman AJ, Hughes EG, Rossi JE, Peng X, Lai M, et al. Anti-NMDA receptor encephalitis: case series and analysis of the effects of antibodies. *Lancet Neurol.* (2008) 7:1091–8. doi: 10.1016/S1474-4422(08)70224-2
7. Camdessanche JP, Streichenberger N, Cavillon G, Rogemond V, Jousserand G, Honnorat J, et al. Brain immunohistopathological study in a patient with anti-NMDAR encephalitis. *Eur J Neurol.* (2011) 18:929–31. doi: 10.1111/j.1468-1331.2010.03180.x
8. Rathcke CN, Vestergaard H. YKL–40, a new inflammatory marker with relation to insulin resistance and with a role in endothelial dysfunction and atherosclerosis. *Inflamm Res.* (2006) 55:221–7. doi: 10.1007/s00011-006-0676-y
9. Craig-Schapiro R, Perrin RJ, Roe CM, Xiong C, Carter D, Cairns NJ, et al. YKL-40: a novel prognostic fluid biomarker for preclinical Alzheimer’s disease. *Brain* (2010) 133( Pt 4):1082–93. doi: 10.1093/brain/awq035
10. Olsson B, Lautner R, Andreasson U, Lådå M, Öhrfelt A, Portelius E, et al. NMDA-receptor antagonists block B-cell function but foster IL-10 production in BCR/CD40-activated B cells. *Cell Comm Signal* (2014) 12:75. doi: 10.1186/s12964-014-0075-5
11. Antonell A, Mansilla A, Rami L, Lladó A, Iranzo A, Olives J, et al. Cerebrospinal fluid level of YKL-40 protein in preclinical and prodromal Alzheimer’s disease. *J Alzheimers Dis.* (2014) 42:901–8. doi: 10.3233/JAD-140624
12. Tanwar MK, Gilbert MR, Holland EC. Gene expression microarray analysis reveals YKL-40 to be a potential serum marker for malignant character in human glioma. *Cancer Res.* (2002) 62:4364–8.
13. Bonneh-Barkay D, Wang G, Starkey A, Hamilton RL, Wiley CA. *In vivo CHI3L1 (YKL-40) expression in astrocytes in acute and chronic neurological disorders.* *J Neuroinflamm.* (2010) 7:34. doi: 10.1186/1742-2094-7-34
14. Östergaard C, Johansen S, Benfield T, Price PA, Lundgren JD. YKL-40 is elevated in cerebrospinal fluid from patients with purulent meningitis. *Clin Diagn Lab Immunol.* (2002) 9:598–604. doi: 10.1128/CDLI.9.3.598-604.2002
15. Alcolea D, Vilaplana E, Preguerols J, Montal V, Sánchez-Juan P, González-Suárez A, et al. Relationship between cortical thickness and cerebrospinal fluid YKL-40 in predementia stages of Alzheimer’s disease. *Neurol Sci.* (2015) 36:2018–23. doi: 10.1007/j.neurolsci.2015.03.001
16. Hachiyi Y, Uruha A, Kasai-Yoshida E, Shimoda K, Sato-Shira i I, Kumada S, et al. Rituximab ameliorates anti-N-methyl-D-aspartate receptor encephalitis by removal of short-lived plasmablasts. *J Neuroinmunol.* (2013) 265:128–30. doi: 10.1016/j.jneuroim.2013.09.017
17. Liu B, Ai P, Zheng D, Jiang Y, Liu X, Pan S, et al. Cerebrospinal fluid pentraxin 3 and CD40 ligand in anti-N-methyl-D-aspartate receptor encephalit is. *J Neuroinmunol.* (2018) 315:40–4. doi: 10.1016/j.jneuroim.2017.11.016
18. Fawcett RG. Acute psychosis associated with anti-NMDA-receptor antibodies and bilateral ovarian teratomas: a case report. *J Clin Psychiatry* (2010) 71:504. doi: 10.4088/JCP.09S5699y
19. Simma N, Rose T, Kalhues S, Mankiewicz J, Lowinus T, Lühe F, et al. NMDA-receptor antagonists block B-cell function but foster IL-10 production in BCR/CD40-activated B cells. *Cell Comm Signal* (2014) 12:75. doi: 10.1186/s12964-014-0075-5
20. Antenell A, Mansilla A, Rami L, Lladó A, Iranzo A, Olives J, et al. Cerebrospinal fluid level of YKL-40 protein in preclinical and prodromal Alzheimer’s disease. *J Alzheimers Dis.* (2014) 42:901–8. doi: 10.3233/JAD-140624
21. Tanwar MK, Gilbert MR, Holland EC. Gene expression microarray analysis reveals YKL-40 to be a potential serum marker for malignant character in human glioma. *Cancer Res.* (2002) 62:4364–8.
22. Bonneh-Barkay D, Wang G, Starkey A, Hamilton RL, Wiley CA. *In vivo CHI3L1 (YKL-40) expression in astrocytes in acute and chronic neurological disorders.* *J Neuroinflamm.* (2010) 7:34. doi: 10.1186/1742-2094-7-34
23. Östergaard C, Johansen S, Benfield T, Price PA, Lundgren JD. YKL-40 is elevated in cerebrospinal fluid from patients with purulent meningitis. *Clin Diagn Lab Immunol.* (2002) 9:598–604. doi: 10.1128/CDLI.9.3.598-604.2002
24. Alcolea D, Vilaplana E, Preguerols J, Montal V, Sánchez-Juan P, González-Suárez A, et al. Relationship between cortical thickness and cerebrospinal fluid YKL-40 in predementia stages of Alzheimer’s disease. *Neurobiol Aging* (2015) 36:2018–23. doi: 10.1016/j.neurobiolaging.2015.03.001
25. Hinsinger G, Gałeotti N, Nabholtz N, Urbach S, Rigau V, Demattei C, et al. Chitinase 3-like proteins as diagnostic and prognostic biomarkers of multiple sclerosis. *Mult Scler.* (2015) 21:1251–61. doi: 10.1177/1352458514561906
26. Burman J, Raininko R, Blennow K, Zetterberg H, Axelsson M, Malmeström C, YKL-40 is a CSF biomarker of intrathecal inflammation in secondary progressive multiple sclerosis. *J Neuroinmunol.* (2016) 292:52–7. doi: 10.1016/j.jneuroim.2016.01.013
27. Wang HH, Dai YQ, Qiu W, Lu ZQ, Peng FH, Wang YG, et al. Interleukin-17-secreting T cells in neuremyelitis optica and multiple sclerosis during relapse. *J Clin Neurosci.* (2011) 18:1313–7. doi: 10.1016/j.jocn.2011.01.031
28. Bhursavij R, Yester JW, Singh SK, Biswas DW, Surace MJ, Waters MR, et al. RelB/p50 complexes regulate cytokine-induced YKL-40 expression. *J Immunol.* (2015) 194:2862–70. doi: 10.4049/jimmunol.1400874
29. Kothur K, Wienholt L, Mohammad SS, Tantissi EM, Pillai S, Britton PN, et al. Utility of CSF cytokine/chemokines as markers of...
active intrathecal inflammation: comparison of demyelinating, anti-NMDAR and enteroviral encephalitis. PLoS ONE (2016) 11:e0161656. doi: 10.1371/journal.pone.0161656

30. Byun JI, Lee SY, Moon J, Jung KH, Sunwoo JS, Lim JA, et al. Distinct intrathecal interleukin-17/interleukin-6 activation in anti-N-methyl-D-aspartate receptor encephalitis. J Neuroimmunol. (2016) 297:141–7. doi: 10.1016/j.jneuroim.2016.05.023

31. Nielsen AR, Plomgaard P, Krabbe KS, Johansen JS, Pedersen BK. IL-6, but not TNF-α, increases plasma YKL-40 in human subjects. Cytokine (2011) 55:152–5. doi: 10.1016/j.cyto.2011.03.014

Conflict of Interest Statement: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Copyright © 2018 Chen, Ding, Zheng, Wang, Pan, Ji, Shen and Wang. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.